| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.28 | 1e-05 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.15 | 4e-05 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.15 | 8e-05 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.21 | 8e-05 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.21 | 0.0001 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.15 | 0.0001 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | 0.3 | 0.0002 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | -0.15 | 0.0002 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | -0.14 | 0.0003 |
| mRNA | Bleomycin | GDSC1000 | pan-cancer | AAC | -0.15 | 0.0003 |